Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL

Bookmark and Share
Published: 7 Dec 2020
Views: 85
Rating:
Save
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Dr Nicholas Short speaks to ecancer about a study he presented at the virtual ASH 2020 meeting on the use of ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL.

He explains that this was a phase I study which examined the combination in 9 patients with the main endpoint being to determine the maximum tolerated dose of venetoclax in the combination.

Dr Short reports that the 800mg daily dose of venetoclax was the highest observed and there were no dose limiting toxicities for this dose.

He also reported that 5 of the 6 patients treated at this dose responded compared with 0 of the 3 treated at the lower dose.